πŸ‡ΊπŸ‡Έ FDA
Patent

US 12318487

Solid tablet dosage form of ridinilazole

granted A61KA61K31/4439A61K31/444

Quick answer

US patent 12318487 (Solid tablet dosage form of ridinilazole) held by SUMMIT (OXFORD) LIMITED expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SUMMIT (OXFORD) LIMITED
Grant date
Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
39
CPC classes
A61K, A61K31/4439, A61K31/444, A61K47/26, A61K9/2018